



### Special Populations:

**Pediatric Patients:** The pharmacokinetics of meloxicam in pediatric patients under 18 years of age have not been investigated.

**Geriatric Patients:** Elderly males ( $\geq 65$  years of age) exhibited meloxicam plasma concentrations and steady state pharmacokinetics similar to young males. Elderly females ( $\geq 65$  years of age) had a 47% higher AUC values and 32% higher  $C_{max}$  values as compared to younger females. The adverse event profile was comparable for elderly male and female patient populations. Free plasma fraction was lower in elderly female patients compared to elderly male patients. **Gender:** Young females exhibited slightly lower plasma concentrations relative to young males.

**Hepatic Insufficiency:** Following a single 15 mg dose of meloxicam there was no difference in plasma concentrations in subjects with mild (Child-Pugh Class I) and moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. No dose adjustment is necessary in mild to moderate hepatic insufficiency. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied.

**Renal Insufficiency:** Total drug plasma concentration is decreased and total clearance of meloxicam is increased in patients with renal insufficiency. There is no need for dose adjustment in patients with mild to moderate renal failure ( $CrCl > 15$  mL/min). Patients with severe renal insufficiency have not been adequately studied. The use of drug in subjects with severe renal impairment is not recommended. The free plasma meloxicam fractions were higher in patients with renal failure on hemodialysis in comparison to healthy volunteers. Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable.

### INDICATIONS :

MEXICAM, is indicated for symptomatic treatment of rheumatoid arthritis, osteoarthritis (arthrosis, degenerative joint disease) and ankylosing spondylitis.

### CONTRAINDICATIONS :

MEXICAM is contraindicated in the following situations; In patients with known hypersensitivity to meloxicam or to any of the excipients of the tablet.

In patients with hypersensitivity to acetylsalicylic acid or other NSAIDs, who have developed signs of asthma, nasal polyps or urticaria following the administration of acetylsalicylic acid or other NSAIDs.

Besides, MEXICAM should not be taken in patients with active peptic ulcer, severe hepatic and renal impairment, children and adolescents aged under 15 years of age, pregnant women and nursing mothers.

### WARNINGS / PRECAUTIONS :

MEXICAM should not be used in individuals who have an active ulcer illness or suffered from the upper gastrointestinal. If it should be used in the ones who had these illnesses beforehand, an anti-ulcer treatment should be applied. Since prostaglandins are necessary for normal kidney function, inhibition of them may cause acute renal failure in especially hypovolemic patients. Thus, MEXICAM should be used carefully in patients whose effective blood volume decreased and who have a hypovolemia risk, and in case of congestive heart failure, cirrhosis, dehydration, surgical operation, nephrotic syndrome, diuretic usage, and kidney functions should be followed up. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) may rarely cause nephrite, nephrosis, and renal medullar necrosis. In advanced renal failure, the dosage should not exceed 7.5 mg per day. If clearance of the creatine is  $> 25$  mL/min, dosage reduction is not required.

MEXICAM should be used carefully in patients who have hemorrhagic diathesis (hemophilia, coagulation, and platelet function disorders). NSAIDs inhibit platelet aggregation and increase risk of the gastrointestinal hemorrhage and ulceration. Slight and temporary variations may be seen at serum transaminase levels during MEXICAM treatment. In case these are permanent and on the highest degree, the treatment should be quitted. It is not clinically required to reduce the dosage in stable liver cirrhosis.

If there are diabetes mellitus, alcoholism, oedema, hypertension, hypovolemia, sepsis in old and imbecilic patients, MEXICAM should be used carefully.

### Use in Pediatric Patients:

Safety and efficacy of meloxicam have not been determined in patients under 18 years of age.

### Use in Geriatric Patients:

As with any NSAID, caution should be exercised in treating the elderly (65 years and older) patients.

### Usage in Pregnancy and Lactation:

#### Pregnancy: Pregnancy Category C.

In experimental researches, congenital malformation and embryo toxicity effects with meloxicam were observed. There are no adequate and well-controlled studies in pregnant women. Meloxicam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

#### Lactation:

In experimental researches, it was determined that meloxicam was excreted in the milk at concentrations higher than those in plasma. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug.

### Effect on Driving and Operating Machinery :

There are no specific studies of the ability to drive and use machinery while using MEXICAM. However, when visual disturbances, drowsiness or vertigo occur, it is advisable to refrain from driving and operating machinery while using the drug.

### SIDE EFFECTS / ADVERSE REACTIONS :

In clinical trials, following side effects were observed in patients who have been treated with daily oral doses of 7.5 or 15 mg meloxicam. Relation of casualty between meloxicam and following side effects has not been determined certainly.

**Gastrointestinal system:** Nausea, vomiting, abdominal pain, diarrhoea, constipation, dyspepsia, meteorism, gastric and duodenal ulcer, oesophagitis, gastrointestinal hemorrhage, colitis, temporary transaminase or increase of bilirubin.

**Cardiovascular system:** Oedema, hypertension, palpitation, flushing.

**Hematologic:** Anemia, leukopenia, thrombocytopenia.

**Respiratory:** Acute asthma (bronchospasm)

**Dermatological:** Pruritus, urticaria, skin rash, stomatitis, photosensitization.

**Central nervous system:** Headache, tinnitus, blurred vision, dizziness.

**Urogenital:** Increase in serum creatin or urea levels

### IN THE EVENT OF AN UNEXPECTED REACTION CONSULT YOUR PHYSICIAN.

### DRUG INTERACTIONS AND OTHER INTERACTIONS :

If NSAIDs are given along with the drugs that decrease the number or function of the platelet, constitute hypoprothrombinemia or, of which potential of gastrointestinal ulceration and hemorrhage formation is high, hemorrhage risk increases.

Usage of MEXICAM together with salicylates or an NSAID increases GI hemorrhage and ulceration and also does not serve an additional therapeutic purpose.

If corticosteroids, corticotrophin, potassium sugar-coated tablets, alcohol are used along with NSAIDs, risk of GI hemorrhage and ulceration increases. When anticoagulants, coumarin or indentionation derivatives, heparin, thrombolytic agents (streptokinase, urokinase, alteplase) are given together with NSAIDs, risk of hemorrhage increases.

Since NSAIDs inhibit renal prostaglandin formation, kidney function may decrease. Sodium and water retention may cause a decrease in the effect of the diuretic and antihypertensive drugs. As a result of decrease in blood volume and renal blood flow after diuretic treatment, acute renal failure may emerge. It has been stated that NSAIDs reduce antihypertensive effect of the Angiotensin Converting Enzyme (ACE) inhibitors, when they are used together.

It has been stated that NSAIDs increase lithium concentrations of blood in patients receiving lithium treatment. Blood levels of the lithium should be observed closely in these patients and, if required, dosage adjustment should be done. NSAIDs increase blood's concentration and toxicity by combining methotrexate with protein and reducing renal elimination. In patients receiving meloxicam treatment,

2200654-A